GERON CORP Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
GERON CORP (GERN) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 56.37 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2024-02-28
- GERON CORP share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2023 was 56.37M shares, a 236.43% increase from fiscal 2022.
- GERON CORP share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2022 was 16.75M shares, a 8.44% decline from fiscal 2021.
- GERON CORP share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2021 was 18.30M shares, a 161.43% increase from fiscal 2020.
- GERON CORP share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2020 was 7.00M shares, a 40.00% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|
| 2023-12-31 | 56.37M shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 16.75M shares 10-K · filed 2023-03-16 |
| 2021-12-31 | 18.30M shares 10-K · filed 2022-03-10 |
| 2020-12-31 | 7.00M shares 10-K · filed 2021-03-11 |
| 2019-12-31 | 5.00M shares 10-K · filed 2020-03-12 |
| 2018-12-31 | 14.00M shares 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |